Literature DB >> 20307840

Beyond cervical cancer: burden of other HPV-related cancers among men and women.

Anil K Chaturvedi1.   

Abstract

Human papillomavirus (HPV) infection is a necessary cause of cervical cancer, and is etiologically associated with a subset of cancers of the anus, oropharynx, penis, vagina, and vulva. Current data indicate that HPV infection is potentially associated with 90%-93% of anal cancers, 12%-63% of oropharyngeal cancers, 36%-40% of penile cancers, 40%-64% of vaginal cancers, and 40%-51% of vulvar cancers. HPV infection accounts for up to 492,800 cervical cancers and 97,215 cases of noncervical HPV-related cancers worldwide during 2002, including up to 50,780 cancers among men (13,485 anal cancers, 26,775 oropharyngeal cancers, and 10,520 penile cancers) and up to 46,435 cancers among women (14,787 anal cancers, 6,048 oropharyngeal cancers, and 25,600 vaginal/vulvar cancers). In the United States annually (1998-2003), up to 10,846 cervical cancers, 4,753 noncervical cancers among men, and 4,128 noncervical cancers among women are potentially attributable to HPV infection. Incidence rates for cervical cancer have declined significantly during the past 30 years in the United States, consistent with the success of Pap smear screening. However, incidence rates for anal, oropharyngeal, and vulvar cancers have increased substantially in recent years. The high proportion of cervical and noncervical cancers caused by HPV types 16 and 18, that is, 70%-76% for cervical cancers and 63%-95% for noncervical cancers, underscores the potential for prevention of a majority of cervical as well as noncervical HPV-related cancers through prophylactic HPV vaccination.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20307840     DOI: 10.1016/j.jadohealth.2010.01.016

Source DB:  PubMed          Journal:  J Adolesc Health        ISSN: 1054-139X            Impact factor:   5.012


  116 in total

1.  A qualitative investigation among men who have sex with men on the acceptability of performing a self- or partner anal exam to screen for anal cancer.

Authors:  Seyram A Butame; Sylvia Lawler; Joseph T Hicks; J Michael Wilkerson; Lu-Yu Hwang; Sarah Baraniuk; Michael W Ross; Elizabeth Yu Chiao; Alan G Nyitray
Journal:  Cancer Causes Control       Date:  2017-08-04       Impact factor: 2.506

2.  Genital human papillomavirus (HPV) concordance in heterosexual couples.

Authors:  Alan G Nyitray; Lynette Menezes; Beibei Lu; Hui-Yi Lin; Dan'elle Smith; Martha Abrahamsen; Mary Papenfuss; Christine Gage; Anna R Giuliano
Journal:  J Infect Dis       Date:  2012-04-26       Impact factor: 5.226

3.  Disparities in HPV Screening and Prevention in Metropolitan and Nonmetropolitan Regions of Michigan.

Authors:  Alexandra Gamber; Joseph Nowatzke; Chin-I Cheng; Allison Hazy; Jacob Kurdys; Emmanuel-Luis Avelino; Neli Ragina
Journal:  J Community Health       Date:  2019-06

Review 4.  Human papillomavirus molecular biology.

Authors:  Mallory E Harden; Karl Munger
Journal:  Mutat Res Rev Mutat Res       Date:  2016-07-05       Impact factor: 5.657

5.  Perceptions of Human Papillomavirus (HPV) infection and acceptability of HPV vaccine among men attending a sexual health clinic differ according to sexual orientation.

Authors:  Massimo Giuliani; Maria Fenicia Vescio; Maria Gabriella Donà; Alessandra Latini; Mirko Frasca; Manuela Colafigli; Massimo Farinella; Giovanni Rezza; Antonio Cristaudo
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

6.  The association between body mass index and anal canal human papillomavirus prevalence and persistence: the HIM study.

Authors:  Alan G Nyitray; Fen Peng; Rena S Day; Roberto J Carvalho Da Silva; Maria Luiza Baggio; Jorge Salmerón; Manuel Quiterio; Martha Abrahamsen; Eduardo Lazcano-Ponce; Luisa L Villa; Anna R Giuliano
Journal:  Hum Vaccin Immunother       Date:  2019-04-19       Impact factor: 3.452

7.  Prevalence of and Risk Factors for Anal Human Papillomavirus Infection in a Sample of Young, Predominantly Black Men Who Have Sex With Men, Houston, Texas.

Authors:  Alan G Nyitray; Kayo Fujimoto; Jing Zhao; Anna R Giuliano; John A Schneider; Lu-Yu Hwang
Journal:  J Infect Dis       Date:  2018-02-14       Impact factor: 5.226

8.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Authors:  Cornelia L Trimble; Matthew P Morrow; Kimberly A Kraynyak; Xuefei Shen; Michael Dallas; Jian Yan; Lance Edwards; R Lamar Parker; Lynette Denny; Mary Giffear; Ami Shah Brown; Kathleen Marcozzi-Pierce; Divya Shah; Anna M Slager; Albert J Sylvester; Amir Khan; Kate E Broderick; Robert J Juba; Timothy A Herring; Jean Boyer; Jessica Lee; Niranjan Y Sardesai; David B Weiner; Mark L Bagarazzi
Journal:  Lancet       Date:  2015-09-17       Impact factor: 79.321

9.  Toxicity and survival of anal cancer patients treated with intensity-modulated radiation therapy.

Authors:  A Ghareeb; K Paramasevon; P Mokool; H van der Voet; M Jha
Journal:  Ann R Coll Surg Engl       Date:  2018-11-28       Impact factor: 1.891

10.  The natural history of genital human papillomavirus among HIV-negative men having sex with men and men having sex with women.

Authors:  Alan G Nyitray; Mihyun Chang; Luisa L Villa; Roberto J Carvalho da Silva; Maria Luiza Baggio; Martha Abrahamsen; Mary Papenfuss; Manuel Quiterio; Jorge Salmerón; Eduardo Lazcano-Ponce; Anna R Giuliano
Journal:  J Infect Dis       Date:  2015-02-03       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.